Montvale, NJ, United States of America

Kihwa Kang

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Regeneron Pharmaceuticals, Inc.. Active years: 2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kihwa Kang. Retrieved from https://idiyas.com/inventor/kihwa-kang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0


 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Journey of Inventor Kihwa Kang

Introduction: Kihwa Kang, a pioneering inventor based in Montvale, NJ (US), has made significant contributions to the field of technology with his groundbreaking inventions and patents.

Latest Patents: Kihwa Kang holds several patents in various technological domains, showcasing his continuous innovation and creativity in the industry.

Career Highlights: Throughout his illustrious career, Kihwa Kang has been recognized for his exceptional problem-solving skills and forward-thinking approach, leading to the development of cutting-edge technologies that have revolutionized the way we live and work.

Collaborations: Kihwa Kang has collaborated with leading research institutions, universities, and innovative companies to further his inventions and bring them to market, solidifying his reputation as a visionary inventor.

Conclusion: In conclusion, Kihwa Kang's dedication to innovation and his relentless pursuit of technological advancement have established him as a prominent figure in the world of inventors, inspiring future generations to push the boundaries of what is possible.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…